Mycin vs micin: one letter, two organisms.

Short answer: the difference between -mycin and -micin is not pharmacological at all. Antibiotics isolated from Streptomyces species are spelled -mycin, and those from Micromonospora species are spelled -micin. The ending records which organism produced the compound, so it tells you nothing about mechanism, class or spectrum.

Why this one looks like a stem and is not

Most generic drug endings are assigned deliberately to mark a pharmacological family, which is what makes them useful. A drug ending in -pril is an ACE inhibitor because a naming committee decided that ending would mean exactly that. Students reasonably generalise the habit and assume every recognisable ending works the same way, and with -mycin and -micin that assumption fails. These two endings predate the modern stem system and encode taxonomy rather than pharmacology, which is why reasoning from them the usual way produces wrong answers. The general system they are the exception to is set out in drug suffixes in pharmacology.

Where the two endings came from

The convention is a historical accident that stuck. Streptomycin, the first aminoglycoside, was isolated from a Streptomyces species in the 1940s, and the ending -mycin was derived from the genus name. When later compounds were isolated from Micromonospora instead, they were given a deliberately distinguishable spelling, blending the new genus with the existing ending to produce -micin [1]. The spelling difference was created to record which organism a compound came from, at a time when source organism was the most useful thing a name could carry. That priority made sense when antibiotics were being discovered by screening soil organisms, and it survives in the names long after the reasoning stopped being clinically relevant. Modern naming reversed that priority deliberately, because a prescriber gains far more from knowing what a drug does than from knowing which soil bacterium produced it. The older antimicrobial names are therefore a snapshot of a period when discovery, not mechanism, was the organising idea in the field.

The evidence that it is taxonomic

The clearest demonstration is that these endings appear across unrelated drug classes. A 2026 review of antibacterial etymology records the suffixes appearing among aminoglycosides, macrolides, rifamycins and polymyxins, and concludes that they function as markers of the producing organism rather than descriptions of how the drugs work [1]. An ending that shows up in four mechanistically unrelated classes cannot be encoding mechanism, which settles the question without needing to memorise anything. The same review notes explicitly that the appearance of these suffixes does not imply a common mechanism of action.

The table that makes it obvious

Read the second and fourth columns together and the point is unmissable. Streptomycin and erythromycin share an ending and share nothing else, since one binds the 30S subunit irreversibly and kills, while the other binds the 50S subunit reversibly and only inhibits growth. Gentamicin and streptomycin are the same class spelled differently, and erythromycin and streptomycin are different classes spelled the same. No amount of attention to the ending resolves that, because the ending is answering a different question from the one being asked.

Antibiotic mechanisms, one drug at a time, on the PharmBit app. Five minutes a day.

Why vancomycin is the hardest case

Vancomycin causes more confusion than any other drug on the list, and for a reason worth understanding. It ends in -mycin, it requires trough monitoring like an aminoglycoside, and it carries nephrotoxicity risk, so three separate signals point the wrong way at once. It is nevertheless a glycopeptide that inhibits cell wall synthesis, which puts it closer to the penicillins in mechanism than to anything ribosomal. The organism it came from was originally classified as a Streptomyces species, which is where the ending came from, and was later reclassified into a different genus without the name changing. Vancomycin is monitored like an aminoglycoside and works like a beta-lactam, which is exactly the combination that makes spelling-based classification fail. The lesson is that shared monitoring requirements do not imply a shared mechanism, since narrow therapeutic index arises independently in unrelated classes.

Why the confusion is clinically dangerous

Mistaking one group for the other is not a harmless naming error, because the two classes differ in every respect that matters for safety. Aminoglycosides have a narrow therapeutic index, require measured peak and trough concentrations, and cause irreversible ototoxicity and dose-related nephrotoxicity. Macrolides require no routine concentration monitoring and carry an entirely different risk profile centred on QT prolongation and cytochrome P450 inhibition. Treating erythromycin as an aminoglycoside would prompt monitoring nobody needs, and treating gentamicin as a macrolide would omit monitoring that prevents permanent deafness. The monitoring logic for the aminoglycosides is set out in aminoglycoside monitoring.

How to tell them apart reliably

Since the ending cannot be trusted, the discrimination has to come from somewhere else, and the most reliable route is the drug's actual identity rather than its spelling. Learn the aminoglycoside members as a short closed list, because there are few of them in common use: gentamicin, amikacin, tobramycin, streptomycin and neomycin. Anything else ending in -mycin is almost certainly not an aminoglycoside. A short memorised class list beats an unreliable spelling rule, and the aminoglycoside list is short enough to make that practical. The clinical context helps too, since aminoglycosides are given parenterally for serious Gram-negative infection while macrolides are typically oral and used for respiratory and atypical organisms. Route alone is a useful first filter, because the aminoglycosides are poorly absorbed from the gut, which is itself a consequence of their highly polar structure rather than an arbitrary fact. Neomycin is the exception that proves it, since it is given orally precisely because it stays in the bowel rather than being absorbed.

What this teaches about stems generally

The useful lesson is broader than one spelling quirk. Drug endings fall into two groups: those assigned by the United States Adopted Names Council and the World Health Organization to mark a pharmacological family, and those inherited from an earlier era that record something else entirely [2]. A stem is only evidence about mechanism if it was assigned to be, which is why the modern endings are reliable and the historical ones are not. Recognising which kind you are looking at is the actual skill, and the older antimicrobial names are where the historical group is concentrated.

How exams test it

Stems exploit the false pattern directly. A question listing erythromycin among aminoglycosides tests whether you classified by spelling. A question asking which agent requires trough monitoring, among a list of similar-sounding drugs, tests the same thing from the safety side. A question pairing gentamicin with a macrolide interaction profile tests it in reverse. Any question offering several similar-sounding antimicrobials is probably testing whether you classify by spelling or by mechanism. The underlying class behaviour is covered in bactericidal vs bacteriostatic antibiotics.

Conclusion

The -mycin and -micin endings record the genus that produced the antibiotic, with Streptomyces giving -mycin and Micromonospora giving -micin. Because they are taxonomic markers rather than assigned pharmacological stems, they appear across aminoglycosides, macrolides, lincosamides and glycopeptides alike, and they predict nothing about target, spectrum or monitoring. Gentamicin and streptomycin are the same class spelled differently, while erythromycin and streptomycin are different classes spelled the same. Learn the short aminoglycoside list instead, and treat this pair as the clearest example of an ending that looks like a stem without behaving like one.

The aminoglycosides among these names are renally cleared and dose-adjusted accordingly: our free creatinine clearance calculator gives the formula, a worked example and the mistake that costs most marks.

Practice questions

For study only. This post explains pharmacology concepts for exam preparation. It is not medical advice. Always follow your course materials, formulary, and supervisor guidance for clinical decisions.

Keep reading

Bactericidal vs bacteriostatic antibiotics

A laboratory definition, not a clinical one. What the MBC/MIC ratio means, why it shifts between labs, and what trials in severe infection actually found.

What does -dipine mean?

The -dipine stem marks a dihydropyridine calcium channel blocker acting on vessels rather than the heart. Why that causes ankle oedema and reflex tachycardia.

What does -floxacin mean?

The -floxacin stem marks a fluoroquinolone inhibiting DNA gyrase. Why tendon rupture, QT prolongation and the chelation interaction all follow from the class.

Drug suffixes in pharmacology: what stems tell you

Stems are assigned by mechanism, so -olol, -pril and -sartan predict the target before you memorise anything. How the system works and exactly where it stops.